Condition: Congenital Cytomegaloviral (CMV) Disease · Sponsor: New York Medical College
Patients with moderate or severe CMV disease less than 21 days old who have a maternal donor who has a CMV response to the peptivators will be screened. All patients will receive treatment with valganciclovir or ganciclovir. There is a safety run in with treatment with CMV CTLs in cohort 1 and if found to be safe, will proceed to cohort 2 for randomization to receive antiviral therapy with or without CMV CTLs. Funding source: FDA OOPD
This description comes directly from the study's public registry record.
Mitchell Cairo, MD · 914-594-2150 · mitchell_cairo@nymc.edu
Edo Schaefer, MD · eshaefe@nymc.edu
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| New York Medical College | Valhalla, New York, United States | Recruiting |
| Nationwide Children's Hosptial | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05564598